Why Caribou Biosciences, Inc.’s (CRBU) Stock Is Down 5.66%
As of Tuesday, July 28, Caribou Biosciences, Inc.’s CRBU share price has dipped by 5.66%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Commentary & Analysis
Why Caribou Biosciences, Inc.’s (CRBU) Stock Is Down 5.52%
As of Monday, July 13, Caribou Biosciences, Inc.’s CRBU share price has dipped by 5.52%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Caribou Biosciences, Inc.’s (CRBU) Stock Is Down 8.25%
As of Friday, July 10, Caribou Biosciences, Inc.’s CRBU share price has dipped by 8.25%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Caribou Biosciences, Inc.’s (CRBU) Stock Is Up 6.25%
As of Wednesday, July 08, Caribou Biosciences, Inc.’s CRBU share price has surged by 6.25%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Caribou Biosciences, Inc.’s (CRBU) Stock Is Up 7.16%
As of Thursday, July 02, Caribou Biosciences, Inc.’s CRBU share price has surged by 7.16%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | CRBU | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $144.8 | $252.6 | 25% |
|
| Shares Out (Mil) | 95.9 | 52.3 | 61% |
|
| Institutional Ownership | 91.6% | 92.1% | 60% |
|
| Float (Mil) | 94.8 | 40.2 | 60% |
|
| Beta | 2.28 | 0.95 | 95% |
|
| Avg Daily Volume (000s) | 1,159 | 455 | 73% |
|
| Price Change (52-week) |
(28.8%) | 52.9% | 26% |
|
| Growth | CRBU | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (2.0%) | 13.6% | 13% |
|
| Net Income (5yr) | (34.0%) | (9.9%) | 11% |
|
| EPS (5yr) | 16.9% | 16.0% | 61 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 57.7% | (15.6%) | 95% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 2 | |
| Current EPS | ($0.307) | ($1.247) | ($1.400) | |
| Month Ago EPS | ($0.307) | ($1.247) | ($1.400) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.340) | ($1.380) | ($1.500) | |
| Year/Year Chg | 17.2% | (21.4%) | 3.1% | |
| Financials | CRBU | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $11 | $38 | 10% |
|
| Net Income (TTM) (Mil) | ($133) | ($43) | 9% |
|
| EPS (TTM) | ($1.414) | ($1.600) | 18% |
|
| Operating Cash Flow (TTM) (Mil) | ($101) | ($31) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($17) | $5 | 27% |
|
| Long-Term Debt (Q1) (Mil) | $26 | $5 | 34% |
|
| Enterprise Value (Q1) (Mil) | $142 | $180 | 24% |
|
| Valuation | CRBU | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.39 | 2.56 | 36% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | CRBU | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (726.6%) | 63.8% | 0% |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (63.0%) | (49.8%) | 9% |
|
| ROE | (83.5%) | (55.5%) | 11% |
|
| Liabilities to Assets | 31.5% | 30.3% | 22% |
|
| F-Score | 3 | 3 | 19% |
|
Caribou Biosciences, Inc. did not pass any screens on 7/31/2026.
